期刊文献+

益钙宁治疗高钙血症的疗效观察 被引量:2

EFFECT OF EEL CALCITONIN ANALOGUE (ELCITONIN) ONHYPERCALCEMIA
原文传递
导出
摘要 用鳗降钙素类似物──益钙宁治疗10例次7例患者高钙血症。经7天观察,血钙在4小时及24小时均显著降低,但48小时回升到近治疗前水平,出现“脱逸”现象,随后几天血钙波动在较高水平。但到第6天血钙再次明显降低,停药后血钙24小时内回升,与第6、7天相比,有显著差异(P<0.002和<0.05).并发现益钙宁的降血钙作用主要通过抑制破骨细胞来实现。 In this article the effect of calcitonin analogue (Elcitonin) on 10 episodes of hypercalcemia in 7 patients was observed. Duringthe 7-day treatment with Elcitonin,serum calcium concentrations were significantly lowered by 4 hours and 24 hours (P<0. 02).By 48 hours, however, serum calcium concentrations returned nearly to pretreatment levels. In the following days, serum calciumconcantrations remained at high levels,this is called the“escape phenomenonn”. By the 6th day,serum calcium concentrations weresubstantially reduced again( P<0- ol).After withdrawal of Elcitonin, serum calcium concentrations rose significantly within 24hours as compared with those on 6th and 7th day, the difference were significant (P<0. 002 vs P<0. 05).This study suggests thatthe calcium-lowering effect of Elcitonin is mainly owed to the effective suppression of osteoclast activity.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 1995年第1期28-31,共4页 Chinese Journal of Endocrinology and Metabolism
关键词 高钙血症 降钙素 脱逸现象 药物疗法 疗效 Hypercalcemia Calcitonin Escaped phenomenon
  • 相关文献

同被引文献32

  • 1周建平,田雨霖.中国人原发性甲状旁腺功能亢进10年文献回顾(1995~2004年)[J].中国普通外科杂志,2007,16(1):78-80. 被引量:44
  • 2Papapoulos SE, Quandt SA, Liberman UA, et al. Meta analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women [J]. Osteoporos Int, 2005, 16 (2) : 468 -474.
  • 3Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France [J]. Clin Ther, 2006, 28 (10) : 1686 - 1694.
  • 4Kastelan D, Lozo P, Stamenkovic D, et al. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: resuhs from the Croatian PROMO Study [ J ]. Clin Rheumatol, 2009, 28 (3): 321-326.
  • 5Blumentals WA, Harris ST, Cole RE, et al. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate [ J ]. Ann Pharmacother, 2009, 43 ( 4 ) : 577 - 585.
  • 6Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis [ J ]. Bone, 2005, 37 (4): 433-440.
  • 7Rizzoli R, Reid DM. Ibandronate : an Ⅳ injection for the treatment for postmenopausal osteoporosis [ J]. Bone, 2007, 41 (5 Suppl 1 ) : S24 - S28.
  • 8Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non - vertebral and clinical fractures in women with postmenopausal os- teoporosis : results of a meta analysis of phase Ⅲ studies [ J ]. Curr Med Res Opin, 2008, 24 (1) : 237 - 245.
  • 9徐少明.努力提高我国原发性甲状旁腺机能亢进症的诊断水平[J].中华医学杂志,1997,77(6):405-406. 被引量:25
  • 10Adami S,Marcocci C,Gatti D. Epidemiology of primary hyperparathy-roidism in Europe[ J]. J Bone Miner Kes,2002,17 ( Suppl 2) : N18-N23.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部